Graviton Bioscience Announces Strategic Investment from Sanofi to Advance Development of the Next Generation of Selective ROCK2 Inhibitors
Summary
Sanofi to receive a 12-month right of first negotiation (ROFN) to explore collaboration opportunities spanning multiple indications, including immunological and metabolic syndrome indicationsNEW YORK, Feb. 1, 2024 /PRNewswire/ -- Graviton Bioscience, a privately held clinical-stage biotechnology company focused on therapies that inhibit Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2), along with other therapeutic compounds, announces a strategic investment from Sanofi. "This investment opens an exciting new chapter for our vision of advancing and commercializing ROCK2 inhibitors, fostering a future that holds promise for patients globally. ""This investment in Graviton Bioscience reflects our commitment to innovative therapies and providing patients with novel medicines and vaccines," added Paul Hudson, Chief Executive Officer, Sanofi. "Cooley LLP is serving as legal advisor to Graviton Bioscience in this strategic partnership.Graviton Bioscience Corporation is a clinical stage drug discovery and development company, dedicated to engineering and developing best-in-class therapeutics for treating CNS, autoimmune, fibrotic, and other serious diseases where ROCK2 and its other therapeutic compounds plays a pivotal role in pathology. A separate formulation of GV101 has completed a Phase 1 single and multiple ascending dose trial in China, also with a favorable safety profile at clinically relevant exposures.